Overall rank by patents
#31,335
of 49,997 tracked assignees
USPTO PatentsView assignee record - 8 granted patents across 4 technology areas, recorded in grant years 2019–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: H01L (Semiconductor Devices NOT Covered BY Class H10).
The verdict
According to USPTO PatentsView, Cusic ranks #31,335 of 49,997 tracked US assignees by granted-patent volume, with 8 patents across 4 technology areas.
USPTO PatentsView assignee plate
Corpus R31335 · Foreign Corporation #31,335 · 8 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-PAR · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL
Nearest grant-volume peer: CTI Biopharma Corp. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
Qualcomm Incorporated · highest
85 score
Cusic · this assignee
23 score
3D Lighting… · lowest
7 score
What this shows Cusic's Innovation Score is 22.7/100 (11th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Cusic Inc. is a focused PatentsView assignee: 4 CPC subclasses with 87.5% of grants classified under H01L (Semiconductor Devices NOT Covered BY Class H10). Peak complete grant year is 2020 (3 grants) versus a trough of 1 in 2019. By volume, Cusic sits between CTI Biopharma Corp. and Cybertoka Ltd..
Cusic Inc. shows 2 grants in 2022–2024 against only 6 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
CTI Biopharma Corp.
8 patents
CTRL-labs Corporation
8 patents
Cubic Tech Corporation
8 patents
Curv Brands, LLC
8 patents
Cutting Edge Spine LLC
8 patents
CY Cergy Paris Universite
8 patents
CY Vision Inc.
8 patents
Cybertoka Ltd.
8 patents
Cusic Inc.
8 patents
What this shows Cusic holds 8 patents at rank #31,234, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #31,234 in granted patent volume.
Other assignees with the most granted patents in Cusic's primary technology class.
Cusic's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
23 11th percentile higher than 11% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2019 | 1 | 12.5% |
| 2020 | 3 | 37.5% |
| 2021 | 2 | 25.0% |
| 2022 | 1 | 12.5% |
| 2024 | 1 | 12.5% |
Top 4 of 4 technology areas
Overall rank by patents
#31,335
of 49,997 tracked assignees
22.7 out of 100
What to do with this data
Cusic Inc.'s patent record in context - here's where to go next.
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.